More on KPTI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.09 |
|
|||
| Open | $7.15 | ||||
| 52 Wk High | $19.41 | ||||
| 52 Wk Low | $4.83 | ||||
| Day High | $7.61 | ||||
| Day Low | $6.99 | ||||
| P/E | N/A | ||||
| EPS | $-2.74 | ||||
| Volume | 900,211 | ||||
- RBC Capital on Karyopharm Therapeutics (KPTI): 'See Buying Oppty On Weakness'
- Form 8-K Karyopharm Therapeutics For: Jul 13
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- H.C. Wainwright Reiterates Buy Rating on Karyopharm Therapeutics (KPTI)
- Karyopharm Therapeutics (KPTI) Reiterated at Overweight by Cantor Fitzgerald
- Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc.
- Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
- Karyopharm cancer trial selected for late-breaking presentation at EHA
- Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
- Karyopharm presents phase 3 trial results at ASCO 2026
Entities mentioned with KPTI
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
